<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04859543</url>
  </required_header>
  <id_info>
    <org_study_id>KDO-2019-001</org_study_id>
    <nct_id>NCT04859543</nct_id>
  </id_info>
  <brief_title>Pediatric Prospective Personalized Immune and Target Identification Trial</brief_title>
  <acronym>PPROSPERITIT</acronym>
  <official_title>Prospective, Interventional Diagnostic, Multicenter, Non-treatment Clinical Study Identifying Specific Molecular Changes by Using Genomic Sequencing Technologies in Refractory/Recurrent or Very High-risk Pediatric CNS Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Masaryk University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PPROSPERITIT is a prospective clinical study assessing the use of comprehensive molecular&#xD;
      profiling to define the best matching targeted and immune treatment for relapsed, refractory&#xD;
      or very high risk pediatric CNS tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPROSPERITIT will identify specific molecular changes by using genomic sequencing&#xD;
      technologies in refractory/recurrent or very high-risk pediatric CNS tumors. The study will&#xD;
      employ an analytically validated comparison of a selection of targeted agents/immune&#xD;
      therapies on the basis of commercially available comprehensive genomic profiling&#xD;
      FoundationOneHeme panel (F1Heme, comprising DNA and RNA analysis) vs selection of agents&#xD;
      based on more complex DNA/RNA/Protein based analyses. This will be coupled to a computer&#xD;
      algorithm that uses preexisting definitions and prioritization of target-agent pairs to&#xD;
      assign patients by actionable mutation results to a targeted treatment. The selection of&#xD;
      targeted agents will be performed by a multidisciplinary molecular tumor board, but the&#xD;
      recommended treatment will not be a part of the PPROSPERTIT study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of patients in which F1Heme molecular testing identified at least 1 clinically relevant alteration at the time of MTB decision.</measure>
    <time_frame>Diagnostic assessment is done within 28 days from enrolment patient in the study.</time_frame>
    <description>Evaluation of the feasibility of FoundationOneHeme</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Pediatric Cancer</condition>
  <condition>GEN1 Gene Mutation</condition>
  <condition>Tumor, Brain</condition>
  <arm_group>
    <arm_group_label>Diagnostic group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Tumor and blood samples will be collected from each patient and broad molecular profiling will be performed. The results of the evaluation of the tumor specimens will determine if the patient's tumor has an actionable mutation for which treatment is available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FoundationOneHeme</intervention_name>
    <description>Tumor tissue obtained during standard surgery will be subsequently examined histopathologically and the content of cancer cells will be determined. Broad molecular profiling of the tumor; with potential results finding such molecular changes, for which the specific targeted anti-tumor treatment will be performed.</description>
    <arm_group_label>Diagnostic group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient Informed consent form must be appropriately obtained under the applicable&#xD;
             local and regulatory requirements. Each patient must sign a consent form prior the&#xD;
             enrollment to document their willingness to participate.&#xD;
&#xD;
          2. The subject is male or female, aged 1 - 19 years&#xD;
&#xD;
          3. The subject must have a histologically proven recurrent/ refractory or very high-risk&#xD;
             CNS tumors&#xD;
&#xD;
          4. Patients must be in good overall physical condition, which allows tumor biopsy&#xD;
&#xD;
          5. Patients must have a life expectancy of at least 3 months.&#xD;
&#xD;
          6. Patients must have a tumor amenable to image-guided or direct vision biopsy and be&#xD;
             willing and able to undergo a tumor biopsy and/or blood taking for molecular&#xD;
             profiling.&#xD;
&#xD;
          7. Patients must be accessible for follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
          2. Pregnant and/or breastfeeding women, if applicable&#xD;
&#xD;
          3. No intention to treat the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaroslav Sterba, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Brno</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristyna Noskova, PhD</last_name>
    <phone>00 420 549 496 147</phone>
    <email>noskova@med.muni.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jana Vinklerova, PhD</last_name>
    <phone>00 420 549 497 782</phone>
    <email>jvinkler@med.muni.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>62500</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Tinka, MD</last_name>
      <phone>00420 532 234 511</phone>
      <email>tinka.pavel@fnbrno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Klara Vejmelkova, MD</last_name>
      <phone>00420 532 234 511</phone>
      <email>vejmelkova.klara@fnbrno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Jaroslav Sterba, Prof., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pavel Tinka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zdenek Pavelka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal Kyr, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Zapotocky, MD, PhD</last_name>
      <phone>00 420 224 436 401</phone>
      <email>michal.zapotocky@fnmotol.cz</email>
    </contact>
    <contact_backup>
      <last_name>David Sumerauer, MD, PhD</last_name>
      <phone>00 420 224 436 401</phone>
      <email>david.sumerauer@fnmotol.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Michal Zapotocky, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Sumerauer, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2021</study_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric oncology, CNS tumors, Personalized medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

